Levodopa-induced Dyskinesia Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ph

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Levodopa-induced Dyskinesia pipeline constitutes key companies continuously working towards developing Levodopa-induced Dyskinesia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Levodopa-induced Dyskinesia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Levodopa-induced Dyskinesia Market.

The Levodopa-induced Dyskinesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Levodopa-induced Dyskinesia Pipeline Report: https://www.delveinsight.com/sample-request/levodopa-induced-dyskinesia-lid-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Levodopa-induced Dyskinesia treatment therapies with a considerable amount of success over the years.
• Levodopa-induced Dyskinesia companies working in the treatment market are Sumitomo Pharma, Neurolixis, Celon Pharma, Bukwang Pharmaceutical, Addex Pharma, and others, are developing therapies for the Levodopa-induced Dyskinesia treatment
• Emerging Levodopa-induced Dyskinesia therapies in the different phases of clinical trials are- DSP-9632P, NLX-112, CPL500036, JM-010, Dipraglurant, and others are expected to have a significant impact on the Levodopa-induced Dyskinesia market in the coming years.
• In March 2023, Intra-Cellular Therapies has commenced a Phase 2 clinical trial, employing a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose design. This study focuses on individuals diagnosed with Parkinson's Disease, as per the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, and currently facing issues related to wearing off symptoms and levodopa-induced dyskinesia.

Levodopa-induced Dyskinesia Overview
Levodopa-induced dyskinesia (LID) refers to the development of abnormal, involuntary movements that can occur as a side effect of long-term treatment with levodopa, a medication commonly used in the management of Parkinson's disease.

Get a Free Sample PDF Report to know more about Levodopa-induced Dyskinesia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/levodopa-induced-dyskinesia-lid-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Levodopa-induced Dyskinesia Drugs Under Different Phases of Clinical Development Include:
• DSP-9632P: Sumitomo Pharma
• NLX-112: Neurolixis
• CPL500036: Celon Pharma
• JM-010: Bukwang Pharmaceutical
• Dipraglurant: Addex Pharma

Levodopa-induced Dyskinesia Route of Administration
Levodopa-induced Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Levodopa-induced Dyskinesia Molecule Type
Levodopa-induced Dyskinesia Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Levodopa-induced Dyskinesia Pipeline Therapeutics Assessment
• Levodopa-induced Dyskinesia Assessment by Product Type
• Levodopa-induced Dyskinesia By Stage and Product Type
• Levodopa-induced Dyskinesia Assessment by Route of Administration
• Levodopa-induced Dyskinesia By Stage and Route of Administration
• Levodopa-induced Dyskinesia Assessment by Molecule Type
• Levodopa-induced Dyskinesia by Stage and Molecule Type

DelveInsight's Levodopa-induced Dyskinesia Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Levodopa-induced Dyskinesia product details are provided in the report. Download the Levodopa-induced Dyskinesia pipeline report to learn more about the emerging Levodopa-induced Dyskinesia therapies at:
https://www.delveinsight.com/sample-request/levodopa-induced-dyskinesia-lid-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Levodopa-induced Dyskinesia Therapeutics Market include:
Key companies developing therapies for Levodopa-induced Dyskinesia are - Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, PharmaTher Inc., Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others.

Levodopa-induced Dyskinesia Pipeline Analysis:
The Levodopa-induced Dyskinesia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Levodopa-induced Dyskinesia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Levodopa-induced Dyskinesia Treatment.
• Levodopa-induced Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Levodopa-induced Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Levodopa-induced Dyskinesia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Levodopa-induced Dyskinesia drugs and therapies-
https://www.delveinsight.com/sample-request/levodopa-induced-dyskinesia-lid-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Levodopa-induced Dyskinesia Pipeline Market Drivers
• Growing prevalence of Parkinson's disease, advancements in research and development • Increasing awareness of LID are some of the important factors that are fueling the Levodopa-induced Dyskinesia Market.

Levodopa-induced Dyskinesia Pipeline Market Barriers
• However, limited treatment options, lack of understanding of underlying mechanisms • Cost of treatment, limited access to care and other factors are creating obstacles in the Levodopa-induced Dyskinesia Market growth.

Scope of Levodopa-induced Dyskinesia Pipeline Drug Insight
• Coverage: Global
• Key Levodopa-induced Dyskinesia Companies: Sumitomo Pharma, Neurolixis, Celon Pharma, Bukwang Pharmaceutical, Addex Pharma, and others
• Key Levodopa-induced Dyskinesia Therapies: DSP-9632P, NLX-112, CPL500036, JM-010, Dipraglurant, and others
• Levodopa-induced Dyskinesia Therapeutic Assessment: Levodopa-induced Dyskinesia current marketed and Levodopa-induced Dyskinesia emerging therapies
• Levodopa-induced Dyskinesia Market Dynamics: Levodopa-induced Dyskinesia market drivers and Levodopa-induced Dyskinesia market barriers

Request for Sample PDF Report for Levodopa-induced Dyskinesia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/levodopa-induced-dyskinesia-lid-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Levodopa-induced Dyskinesia Report Introduction
2. Levodopa-induced Dyskinesia Executive Summary
3. Levodopa-induced Dyskinesia Overview
4. Levodopa-induced Dyskinesia- Analytical Perspective In-depth Commercial Assessment
5. Levodopa-induced Dyskinesia Pipeline Therapeutics
6. Levodopa-induced Dyskinesia Late Stage Products (Phase II/III)
7. Levodopa-induced Dyskinesia Mid Stage Products (Phase II)
8. Levodopa-induced Dyskinesia Early Stage Products (Phase I)
9. Levodopa-induced Dyskinesia Preclinical Stage Products
10. Levodopa-induced Dyskinesia Therapeutics Assessment
11. Levodopa-induced Dyskinesia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Levodopa-induced Dyskinesia Key Companies
14. Levodopa-induced Dyskinesia Key Products
15. Levodopa-induced Dyskinesia Unmet Needs
16 . Levodopa-induced Dyskinesia Market Drivers and Barriers
17. Levodopa-induced Dyskinesia Future Perspectives and Conclusion
18. Levodopa-induced Dyskinesia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Levodopa-induced Dyskinesia Market https://www.delveinsight.com/report-store/levodopa-induced-dyskinesia-lid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Levodopa-induced Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Levodopa-induced Dyskinesia Epidemiology delveinsight.com/report-store/levodopa-induced-dyskinesia-lid-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Levodopa-induced Dyskinesia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Telemedicine Service Market https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost

Wearable Medical Devices Market https://www.delveinsight.com/report-store/wearable-medical-devices-market
Wearable Medical Devices Market By Device Type (Diagnostic And Monitoring Devices [Vital Sign Monitoring Devices, Sleep Monitoring Devices, Electrocardiographs Fetal And Obstetric Devices, Neuromonitoring Devices, And Others] And Therapeutic Devices [Pain Management Devices, Rehabilitation Devices, Respiratory Therapy Devices, And Others]), By Product Type (Wristband, Headband, Ear Wear, Watch, And Others), By Application (Sports And Fitness, Remote Patient Monitoring, And Home Healthcare), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to a rise in the geriatric population and increasing prevalence of chronic diseases across the globe.

Surgical Robotic System Market https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Robotic Systems Market By Application (Urology, Gynecology, Neurosurgery, Orthopedics, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), And by geography is estimated to register appreciable CAGR forecast till 2028 owing to increase in surgical procedures and rising popularity of minimally invasive surgical interventions.

Cancer Diagnostics Market
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent & Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast till 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to lauch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.